Relativistic Kinetics of Phonon Gas in Superfluids

The relativistic kinetic theory of the phonon gas in superfluids is developed. The technique of the derivation of macroscopic balance equations from microscopic equations of motion for individual particles is applied to an ensemble of quasi-particles. The necessary expressions are constructed in terms of a Hamilton function of a (quasi-)particle. A phonon contribution into superfluid dynamic parameters is obtained from energy-momentum balance equations for the phonon gas together with the conservation law for superfluids as a whole. Relations between dynamic flows being in agreement with results of relativistic hydrodynamic consideration are found. Based on the kinetic approach a problem of relativistic variation of the speed of sound under phonon influence at low temperature is solved.Comment: 23 pages, Revtex fil

Kernel density classification and boosting: an L2 sub analysis

Kernel density estimation is a commonly used approach to classification. However, most of the theoretical results for kernel methods apply to estimation per se and not necessarily to classification. In this paper we show that when estimating the difference between two densities, the optimal smoothing parameters are increasing functions of the sample size of the complementary group, and we provide a small simluation study which examines the relative performance of kernel density methods when the final goal is classification. A relative newcomer to the classification portfolio is “boosting”, and this paper proposes an algorithm for boosting kernel density classifiers. We note that boosting is closely linked to a previously proposed method of bias reduction in kernel density estimation and indicate how it will enjoy similar properties for classification. We show that boosting kernel classifiers reduces the bias whilst only slightly increasing the variance, with an overall reduction in error. Numerical examples and simulations are used to illustrate the findings, and we also suggest further areas of research

Certain subclasses of multivalent functions defined by new multiplier transformations

In the present paper the new multiplier transformations \mathrm{{\mathcal{J}% }}_{p}^{\delta }(\lambda ,\mu ,l) (\delta ,l\geq 0,\;\lambda \geq \mu \geq 0;\;p\in \mathrm{% }%\mathbb{N} )} of multivalent functions is defined. Making use of the operator $\mathrm{{\mathcal{J}}}_{p}^{\delta }(\lambda ,\mu ,l),$ two new subclasses $\mathcal{P}_{\lambda ,\mu ,l}^{\delta }(A,B;\sigma ,p)$ and $\widetilde{\mathcal{P}}_{\lambda ,\mu ,l}^{\delta }(A,B;\sigma ,p)$\textbf{\ }of multivalent analytic functions are introduced and investigated in the open unit disk. Some interesting relations and characteristics such as inclusion relationships, neighborhoods, partial sums, some applications of fractional calculus and quasi-convolution properties of functions belonging to each of these subclasses $\mathcal{P}_{\lambda ,\mu ,l}^{\delta }(A,B;\sigma ,p)$ and $\widetilde{\mathcal{P}}_{\lambda ,\mu ,l}^{\delta }(A,B;\sigma ,p)$ are investigated. Relevant connections of the definitions and results presented in this paper with those obtained in several earlier works on the subject are also pointed out

Minimum mass of galaxies from BEC or scalar field dark matter

Many problems of cold dark matter models such as the cusp problem and the missing satellite problem can be alleviated, if galactic halo dark matter particles are ultra-light scalar particles and in Bose-Einstein condensate (BEC), thanks to a characteristic length scale of the particles. We show that this finite length scale of the dark matter can also explain the recently observed common central mass of the Milky Way satellites ($\sim 10^7 M_\odot$) independent of their luminosity, if the mass of the dark matter particle is about $10^{-22} eV$.Comment: 10 pages, 1 figure, accepted in JCA

Fermi 130 GeV gamma-ray excess and dark matter annihilation in sub-haloes and in the Galactic centre

We analyze publicly available Fermi-LAT high-energy gamma-ray data and confirm the existence of clear spectral feature peaked at E=130GeV. Scanning over the Galaxy we identify several disconnected regions where the observed excess originates from. Our best optimized fit is obtained for the central region of Galaxy with a clear peak at 130GeV with local statistical significance 4.5 sigma. The observed excess is not correlated with Fermi bubbles. We compute the photon spectra induced by dark matter annihilations into two and four standard model particles, the latter via two light intermediate states, and fit the spectra with data. Since our fits indicate sharper and higher signal peak than in the previous works, data favors dark matter direct two-body annihilation channels into photons or other channels giving only line-like spectra. If Einasto halo profile correctly predicts the central cusp of Galaxy, dark matter annihilation cross-section to two photons is of order ten percent of the standard thermal freeze-out cross-section. The large dark matter two-body annihilation cross-section to photons may signal a new resonance that should be searched for at the CERN LHC experiments.Comment: Addendum included on the double peak structure of the excess seen due to new improved Fermi-LAT energy resolutio

Smoothing and Matching of 3-D Space Curves

International audienceWe present a new approach to the problem of matching 3-D curves. The approach has a low algorithmic complexity in the number of models, and can operate in the presence of noise and partial occlusions. Our method builds upon the seminal work of Kishon et al. (1990), where curves are first smoothed using B-splines, with matching based on hashing using curvature and torsion measures. However, we introduce two enhancements: -- We make use of nonuniform B-spline approximations, which permits us to better retain information at highcurvature locations. The spline approximations are controlled (i.e., regularized) by making use of normal vectors to the surface in 3-D on which the curves lie, and by an explicit minimization of a bending energy. These measures allow a more accurate estimation of position, curvature, torsion, and Frtnet frames along the curve. -- The computational complexity of the recognition process is relatively independent of the number of models and is considerably decreased with explicit use of the Frtnet frame for hypotheses generation. As opposed to previous approaches, the method better copes with partial occlusion. Moreover, following a statistical study of the curvature and torsion covariances, we optimize the hash table discretization and discover improved invariants for recognition, different than the torsion measure. Finally, knowledge of invariant uncertainties is used to compute an optimal global transformation using an extended Kalman filter. We present experimental results using synthetic data and also using characteristic curves extracted from 3-D medical images. An earlier version of this article was presented at the 2nd European Conference on Computer Vision in Italy

BIOLEACHING OF COBALT AND ZINC FROM PYRITE ORE IN RELATION TO CALCITIC GANGUE CONTENT

Bioleaching of a pyrite ore containing high concentrations of cobalt (0.1%) and zinc (0.065%) was affected by small amounts of calcitic gangue (from 0.01 to 1.01%). Results from an air-lift percolator and from Erlenmeyer flask experiments show that a small percentage of calcite raises the pH and arrests the growth of the acidophilic bacterium Thiobacillus ferrooxidans. In percolator experiments, when calcite is completely removed by the continuous addition of small quantities of acid, and the pH of the liquor becomes acid, the micro-organism begins to grow and to bio-oxidize the pyrite ore. The growth of T. ferrooxidans shows different lag phase spans (from 13 to 190 days) depending on carbonate dissolution. The metals Fe, Zn and Co are released into the leaching solution together at different rates after a lag-time which depends on calcite concentrations in pyrite gangue. Metal ratios in the mineral bulk are different from those in the liquor, Zn dissolving 5 times more readily than Co. Bioleaching rates for metal removal from pyrite are higher in percolator (for Fe, from 5 to 15 mg/l/h) than in flask experiments (from 0.5 to 2 mg/l/h), but the lag phases are shorter (from 2 to 65 days). The differences between the two systems are related to calcite dissolution and gypsum precipitation

Dapagliflozin and cardiovascular outcomes in type 2 diabetes

BACKGROUND The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium– glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is undefined. METHODS We randomly assigned patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease to receive either dapagliflozin or placebo. The primary safety outcome was a composite of major adverse cardiovascular events (MACE), defined as cardiovascular death, myocardial infarction, or ischemic stroke. The primary efficacy outcomes were MACE and a composite of cardiovascular death or hospitalization for heart failure. Secondary efficacy outcomes were a renal composite (≥40% decrease in estimated glomerular filtration rate to <60 ml per minute per 1.73 m2 of body-surface area, new end-stage renal disease, or death from renal or cardiovascular causes) and death from any cause. RESULTS We evaluated 17,160 patients, including 10,186 without atherosclerotic cardiovascular disease, who were followed for a median of 4.2 years. In the primary safety outcome analysis, dapagliflozin met the prespecified criterion for noninferiority to placebo with respect to MACE (upper boundary of the 95% confidence interval [CI], <1.3; P<0.001 for noninferiority). In the two primary efficacy analyses, dapagliflozin did not result in a lower rate of MACE (8.8% in the dapagliflozin group and 9.4% in the placebo group; hazard ratio, 0.93; 95% CI, 0.84 to 1.03; P=0.17) but did result in a lower rate of cardiovascular death or hospitalization for heart failure (4.9% vs. 5.8%; hazard ratio, 0.83; 95% CI, 0.73 to 0.95; P=0.005), which reflected a lower rate of hospitalization for heart failure (hazard ratio, 0.73; 95% CI, 0.61 to 0.88); there was no between-group difference in cardiovascular death (hazard ratio, 0.98; 95% CI, 0.82 to 1.17). A renal event occurred in 4.3% in the dapagliflozin group and in 5.6% in the placebo group (hazard ratio, 0.76; 95% CI, 0.67 to 0.87), and death from any cause occurred in 6.2% and 6.6%, respectively (hazard ratio, 0.93; 95% CI, 0.82 to 1.04). Diabetic ketoacidosis was more common with dapagliflozin than with placebo (0.3% vs. 0.1%, P=0.02), as was the rate of genital infections that led to discontinuation of the regimen or that were considered to be serious adverse events (0.9% vs. 0.1%, P<0.001). CONCLUSIONS In patients with type 2 diabetes who had or were at risk for atherosclerotic cardiovascular disease, treatment with dapagliflozin did not result in a higher or lower rate of MACE than placebo but did result in a lower rate of cardiovascular death or hospitalization for heart failure, a finding that reflects a lower rate of hospitalization for heart failure. (Funded by AstraZeneca; DECLARE–TIMI 58 ClinicalTrials.gov number, NCT01730534.

Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2)

BACKGROUND: Worldwide data for cancer survival are scarce. We aimed to initiate worldwide surveillance of cancer survival by central analysis of population-based registry data, as a metric of the effectiveness of health systems, and to inform global policy on cancer control. METHODS: Individual tumour records were submitted by 279 population-based cancer registries in 67 countries for 25·7 million adults (age 15-99 years) and 75,000 children (age 0-14 years) diagnosed with cancer during 1995-2009 and followed up to Dec 31, 2009, or later. We looked at cancers of the stomach, colon, rectum, liver, lung, breast (women), cervix, ovary, and prostate in adults, and adult and childhood leukaemia. Standardised quality control procedures were applied; errors were corrected by the registry concerned. We estimated 5-year net survival, adjusted for background mortality in every country or region by age (single year), sex, and calendar year, and by race or ethnic origin in some countries. Estimates were age-standardised with the International Cancer Survival Standard weights. FINDINGS: 5-year survival from colon, rectal, and breast cancers has increased steadily in most developed countries. For patients diagnosed during 2005-09, survival for colon and rectal cancer reached 60% or more in 22 countries around the world; for breast cancer, 5-year survival rose to 85% or higher in 17 countries worldwide. Liver and lung cancer remain lethal in all nations: for both cancers, 5-year survival is below 20% everywhere in Europe, in the range 15-19% in North America, and as low as 7-9% in Mongolia and Thailand. Striking rises in 5-year survival from prostate cancer have occurred in many countries: survival rose by 10-20% between 1995-99 and 2005-09 in 22 countries in South America, Asia, and Europe, but survival still varies widely around the world, from less than 60% in Bulgaria and Thailand to 95% or more in Brazil, Puerto Rico, and the USA. For cervical cancer, national estimates of 5-year survival range from less than 50% to more than 70%; regional variations are much wider, and improvements between 1995-99 and 2005-09 have generally been slight. For women diagnosed with ovarian cancer in 2005-09, 5-year survival was 40% or higher only in Ecuador, the USA, and 17 countries in Asia and Europe. 5-year survival for stomach cancer in 2005-09 was high (54-58%) in Japan and South Korea, compared with less than 40% in other countries. By contrast, 5-year survival from adult leukaemia in Japan and South Korea (18-23%) is lower than in most other countries. 5-year survival from childhood acute lymphoblastic leukaemia is less than 60% in several countries, but as high as 90% in Canada and four European countries, which suggests major deficiencies in the management of a largely curable disease. INTERPRETATION: International comparison of survival trends reveals very wide differences that are likely to be attributable to differences in access to early diagnosis and optimum treatment. Continuous worldwide surveillance of cancer survival should become an indispensable source of information for cancer patients and researchers and a stimulus for politicians to improve health policy and health-care systems